Severe irAEs (cutaneous and noncutaneous) | All-grade cutaneous irAEs[1] | Severe cutaneous irAEs[1] | |
Ipilimumab monotherapy[2] | 10 to 15% | 22 to 44% | 2% |
Nivolumab monotherapy[3-5] | 5 to 14% | 11 to 37% | 0.4 to 14% |
Pembrolizumab monotherapy[6-8] | 3 to 15% | 11% | 0.2 to 2.4% |
Atezolizumab monotherapy[9] | 18% | 42% | 2% |
Ipilimumab and nivolumab combination therapy[10] | 59% | 62% | 6% |
Ipilimumab and pembrolizumab combination therapy[11] | 46% | 42% | 9% |
References:
Do you want to add Medilib to your home screen?